Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019155
Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology – A systematic review and meta-analysis.106
Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer83
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes79
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer71
Clinical assays for assessment of homologous recombination DNA repair deficiency71
Uterine serous carcinoma70
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity69
Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study69
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes66
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer65
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment64
Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses60
Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers60
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial59
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations57
Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer56
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial54
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer54
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis51
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study49
Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study48
Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends45
Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature45
Homologous recombination deficiency real-time clinical assays, ready or not?44
Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update44
Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma42
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer42
Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer42
Natural language processing with machine learning to predict outcomes after ovarian cancer surgery42
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian can41
Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for “low-risk” early-stage cervical cancer: A propensity-score based analysis41
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review41
Non-coding RNAs related to angiogenesis in gynecological cancer39
GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function39
Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer38
Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals37
0.075520038604736